{"id":"ebp05","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by mimicking the action of GLP-2, a naturally occurring peptide hormone that promotes intestinal growth and adaptation. This can lead to improved nutrient absorption and potentially enhanced recovery from gastrointestinal damage.","oneSentence":"EBP05 is a recombinant human glucagon-like peptide-2 (GLP-2) analog.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:36:25.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Short bowel syndrome"}]},"trialDetails":[{"nctId":"NCT05965167","phase":"PHASE1","title":"Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo","status":"COMPLETED","sponsor":"Entera Bio Ltd.","startDate":"2023-05-11","conditions":"Hypoparathyroidism, Osteoporosis, Fractures, Bone","enrollment":45},{"nctId":"NCT04003467","phase":"PHASE2","title":"A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass","status":"COMPLETED","sponsor":"Entera Bio Ltd.","startDate":"2019-06-30","conditions":"Osteoporosis","enrollment":161},{"nctId":"NCT03516773","phase":"PHASE2","title":"Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism","status":"COMPLETED","sponsor":"Entera Bio Ltd.","startDate":"2018-06-17","conditions":"Hypoparathyroidism","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["hPTH(1-34)","Teriparatide"],"phase":"phase_2","status":"active","brandName":"EBP05","genericName":"EBP05","companyName":"Entera Bio Ltd.","companyId":"entera-bio-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EBP05 is a recombinant human glucagon-like peptide-2 (GLP-2) analog. Used for Short bowel syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}